ctDNA measurement: Blood samples are collected as part of standard of care and ctDNA measurements will be performed on these samples.
Study summary
The goal of this study is to assess the implementation and feasibility of ctDNA measurements from blood samples obtained during routine clinical care of cancer patients in the University Hospital Basel.
Researchers will compare clinical and patient reported outcomes from the LIQPLAT study with patients who did not receive ctDNA measurements (external comparator from registry AO\_2023-00091).
Blood samples will be drawn from the patients as part of routine care and ctDNA measurements will be performed on these samples.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients with a proven solid malignant disease, i.e. with solid malignant tumors where no primary surgical resection is planned OR solid malignant tumors that are locally advanced and inoperable OR solid tumors that are metastatic
* No prior treatment for advanced/metastatic disease
* Indication for medical anti-cancer treatment (including combined chemoradiotherapy) as judged by the treating physician
* Patient age 18 years and older
* General research consent of the University Hospital Basel
Exclusion Criteria:
● Patients with primary brain tumors
Primary outcome measure(s)
Number and proportion of patients in whom ctDNA was detectable before starting medical anticancer treatment — 1 time assessment at baseline Number and proportion of patients in whom ctDNA was detectable before starting medical anticancer treatment. Calculated as the number of patients with detectable ctDNA over the total number of patients included, expressed as a percentage.
Patients in whom actionable alterations were identified in ctDNA analysis — baseline, between month 2 and 3, between month 5 and 6, clinical event Patients in whom actionable alterations were identified in ctDNA analysis. Calculated as the number of patients with actionable alterations over the total number of patients included, expressed as a percentage.
Clinical event is defined as suspicious or confirmed clinical or radiological disease progression or treatment discontinuation for any reason.
Turn-around time of ctDNA analysis — baseline, between month 2 and 3, between month 5 and 6, clinical event Time from ctDNA request until issuing the first report. Expressed as hours.
Clinical event is defined as suspicious or confirmed clinical or radiological disease progression or treatment discontinuation for any reason.
ctDNA kinetics — up to 24 months Change in allelic frequency over time including relative changes from baseline.
Trial sites (1)
Facility
City
Region
Status
Department of Medical Oncology, University Hospital Basel
Basel
Switzerland
More University Hospital, Basel, Switzerland trials in Switzerland
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
